Subcutaneous immunoglobulin (SCIg) therapy is indicated in primary and secondary @entity1200 . Its use in practice is being extended to @entity792 . Few studies investigated the feasibility and safety of SCIg in these rare conditions. The aim was to describe the use of SCIg in @entity5442 including @entity6558 ( @entity6558 ), @entity6017 ( @entity6017 ) and @entity5589 ( @entity5589 ), in real-life settings. This case series was based upon a retrospective data collection. The primary objective was to assess the feasibility of the SCIg injections for the treatment of @entity792 and adherence to high doses. Secondary objectives included safety and efficacy. Nineteen cases were identified: 7 @entity1 were diagnosed with @entity6558 , 7 with @entity5589 , 2 with @entity6017 , and 3 with @entity5442 associated with connective tissue disease. @entity1 were treated and followed-up for a mean duration of 18.8months (range 4.5-42). They received a median of 64 SCIg infusions and a total of 1215 infusions. Out of 14 @entity1 , 10 showed an improvement in muscle strength, and 7 out of 11 showed an improvement in @entity121 scale. Two @entity1 were lost to follow-up. Few slight adverse reactions were reported including mainly mild @entity10 and local skin reactions. Any serious adverse event was reported. These results suggest that the use of high-dose SCIg is feasible, beneficial and safe in @entity1 with @entity5442 . SCIg could be an alternative of IVIg in @entity1 with difficult venous access or with insufficient response, and in @entity1 preferring home care setting.

Long-term subcutaneous immunoglobulin use in XXXX : A retrospective review of 19 cases.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity6017 :: ('MESH:D003882', 'Disease') :: ['dermatomyositis', 'DM'] @entity5442 :: ('MESH:D009220', 'Disease') :: ['myositis', 'inflammatory myopathies'] @entity121 :: ('MESH:D009135', 'Disease') :: ['muscle disability'] @entity1200 :: ('MESH:D007154', 'Disease') :: ['immunodeficiency diseases'] @entity5589 :: ('MESH:D018979', 'Disease') :: ['inclusion body myositis', 'IBM'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headaches'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune diseases'] @entity6558 :: ('MESH:D017285', 'Disease') :: ['PM', 'polymyositis']
@entity5442 :: (MESH:D009220,Disease) :: ['inflammatory myopathies']
